In breast cancer, the ETS (E26 transformation-specific) transcription factor 7 (EVT7) has been identified to temper the inflammatory response by inhibiting the TNFR 1/NF-κB axis, a crucial determinant of drug resistance 40, 41. Here, NFKB1 is linked to breast cancer.